LFSC vs. PBE

Last updated Jun 4, 2026

LFSC (F/m Emerald Life Sciences Innovation ETF) and PBE (Invesco Dynamic Biotechnology & Genome ETF) are both Health & Biotech Equities funds. LFSC is actively managed, while PBE is passively managed. Over the past year, LFSC returned 58.79% vs 30.26% for PBE. A 0.71 correlation means they provide meaningful diversification when combined. LFSC charges 0.54%/yr vs 0.59%/yr for PBE.

Performance

LFSC vs. PBE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in F/m Emerald Life Sciences Innovation ETF (LFSC) and Invesco Dynamic Biotechnology & Genome ETF (PBE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, LFSC achieves a 3.84% return, which is significantly higher than PBE's 0.58% return.

LFSC

• 1D: 1.08%
• 1M: -1.63%
• YTD: 3.84%
• 6M: 1.68%
• 1Y: 58.79%
• 3Y*: —
• 5Y*: —
• 10Y*: —

PBE

• 1D: 2.04%
• 1M: 2.68%
• YTD: 0.58%
• 6M: 1.15%
• 1Y: 30.26%
• 3Y*: 10.44%
• 5Y*: 3.06%
• 10Y*: 7.55%

*Multi-year figures are annualized to reflect compound growth (CAGR)

LFSC vs. PBE - Yearly Performance Comparison

	2026 (YTD)	2025	2024
LFSC F/m Emerald Life Sciences Innovation ETF	3.84%	56.54%	-6.02%
PBE Invesco Dynamic Biotechnology & Genome ETF	0.58%	24.84%	-2.45%

Correlation

The correlation between LFSC and PBE is 0.67, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.67
Correlation (All Time) Calculated using the full available price history since Nov 1, 2024	0.71

The correlation between LFSC and PBE has been stable across timeframes, ranging from 0.67 to 0.71 - a consistent structural relationship.

Return for Risk

LFSC vs. PBE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LFSC

LFSC Risk / Return Rank: 67
LFSC Sharpe Ratio Rank: 70
LFSC Sortino Ratio Rank: 70
LFSC Omega Ratio Rank: 62
LFSC Calmar Ratio Rank: 73
LFSC Martin Ratio Rank: 58

PBE

PBE Risk / Return Rank: 47
PBE Sharpe Ratio Rank: 46
PBE Sortino Ratio Rank: 49
PBE Omega Ratio Rank: 44
PBE Calmar Ratio Rank: 52
PBE Martin Ratio Rank: 44

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LFSC vs. PBE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for F/m Emerald Life Sciences Innovation ETF (LFSC) and Invesco Dynamic Biotechnology & Genome ETF (PBE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LFSC	PBE	Difference
Sharpe ratio: Return per unit of total volatility	2.28	1.63	+0.65
Sortino ratio: Return per unit of downside risk	3.19	2.44	+0.74
Omega ratio: Gain probability vs. loss probability	1.38	1.28	+0.09
Calmar ratio: Return relative to maximum drawdown	3.64	2.59	+1.05
Martin ratio: Return relative to average drawdown	10.14	7.27	+2.87
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LFSC vs. PBE - Sharpe Ratio Comparison

The current LFSC Sharpe Ratio is 2.28, which is higher than the PBE Sharpe Ratio of 1.63. The chart below compares the historical Sharpe Ratios of LFSC and PBE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	LFSC	PBE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.28	1.63	+0.65
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.14	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.30	—
Sharpe Ratio (All Time) Calculated using the full available price history	1.07	0.32	+0.75

Drawdowns

LFSC vs. PBE - Drawdown Comparison

The maximum LFSC drawdown since its inception was -29.74%, smaller than the maximum PBE drawdown of -45.69%. Use the drawdown chart below to compare losses from any high point for LFSC and PBE.

Drawdown Indicators

	LFSC	PBE	Difference
Max Drawdown Largest peak-to-trough decline	-29.74%	-45.69%	+15.95%
Max Drawdown (1Y) Largest decline over 1 year	-16.25%	-11.73%	-4.52%
Max Drawdown (3Y) Largest decline over 3 years	—	-22.43%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-34.71%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-37.84%	—
Current Drawdown Current decline from peak	-3.57%	-3.62%	+0.05%
Average Drawdown Average peak-to-trough decline	-7.82%	-16.24%	+8.42%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.82%	4.17%	+1.65%

Volatility

LFSC vs. PBE - Volatility Comparison

F/m Emerald Life Sciences Innovation ETF (LFSC) has a higher volatility of 7.43% compared to Invesco Dynamic Biotechnology & Genome ETF (PBE) at 5.63%. This indicates that LFSC's price experiences larger fluctuations and is considered to be riskier than PBE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LFSC	PBE	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.43%	5.63%	+1.80%
Volatility (6M) Calculated over the trailing 6-month period	18.52%	13.27%	+5.25%
Volatility (1Y) Calculated over the trailing 1-year period	26.01%	18.71%	+7.30%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	28.90%	22.54%	+6.36%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	28.90%	24.92%	+3.98%

LFSC vs. PBE - Expense Ratio Comparison

LFSC has a 0.54% expense ratio, which is lower than PBE's 0.59% expense ratio.

Dividends

LFSC vs. PBE - Dividend Comparison

LFSC has not paid dividends to shareholders, while PBE's dividend yield for the trailing twelve months is around 1.05%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
LFSC F/m Emerald Life Sciences Innovation ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
PBE Invesco Dynamic Biotechnology & Genome ETF	1.05%	1.00%	0.05%	0.02%	0.00%	0.00%	0.04%	0.00%	0.00%	0.57%	0.38%	1.12%

Frequently Asked Questions

Can I hold both LFSC and PBE in my portfolio?

LFSC and PBE have a correlation of 0.67, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, LFSC or PBE?

LFSC has higher volatility (7.43%) compared to PBE (5.63%). In terms of maximum drawdown, LFSC dropped -29.74% vs PBE's -45.69%.

Which ETF is better, LFSC or PBE?

On 1-year performance, LFSC leads with 58.79% vs 30.26% for PBE. On fees, LFSC is cheaper at 0.54% per year. On volatility, PBE has been the lower-risk option at 5.63%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, LFSC or PBE?

Over the 1-year period, LFSC has performed better with a 58.79% return vs 30.26%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, LFSC or PBE?

LFSC is cheaper with a 0.54% expense ratio, compared with 0.59% for PBE.

Which ETF pays a higher dividend yield, LFSC or PBE?

PBE has the higher dividend yield at 1.05%, compared with 0.00% for LFSC.

What is the main difference between LFSC and PBE?

They also come from different issuers: F/m Investments and Invesco. Their fees differ too: 0.54% for LFSC and 0.59% for PBE.

Which has better risk-adjusted returns?

LFSC currently has the higher Sharpe Ratio (2.28 vs 1.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.